跳到正文
原文
MedTech Dive 器械媒体· Nick Paul Taylor·· 2026-10-12精选AI 评分79

FDA通报飞利浦Lumify超声系统更新使用指导

Philips updates instructions for ultrasound system linked to 4 deaths

AI 导读

FDA周五发布早期警报称,飞利浦已更新便携式Lumify诊断超声系统的使用指导,此前共报告8例严重伤害和4例死亡。问题源于Lumify的Android或iOS应用无法识别已注册探头,要求重新注册且需Wi-Fi或蜂窝信号,导致在无线网或信号弱的环境无法扫描,可能延误诊疗。飞利浦建议除非有备用超声设备,否则仅在Wi-Fi或蜂窝信号易达区域使用,并正开发软件更新和排查USB连接不稳定问题。

推荐理由

FDA早期警报指向Lumify因信号依赖导致扫描延迟的具体风险场景,可供评估移动超声使用条件。

正文 · 原文

An article from site logo

Dive Brief

A software issue can delay use of the Lumify diagnostic ultrasound system in environments without access to Wi-Fi or cellular signal.

Published Oct. 12, 2026

By

Philips wrote to customers about the issue last month. Patrik Stollarz / Staff via Getty Images

Dive Brief:

  • Philips is updating instructions for an ultrasound system after reporting eight serious injuries and four deaths, the Food and Drug Administration said Friday.
  • The FDA, which published an early alert about Philips’ actions, said the software issue can delay the use of the portable Lumify diagnostic ultrasound system.
  • Philips wrote to customers about the issue last month, recommending actions to mitigate the risks while it develops a software update to fix the problem.

Dive Insight:

The risks stem from the failure of Lumify Android or iOS applications to recognize a previously registered transducer. When that happens, the system prompts users to re-register the devices. The Lumify device cannot be used to scan patients until re-registration is complete.

Re-registration requires Wi-Fi or cellular signal access, making the issue a particular concern for devices used outside of hospitals. Lumify is intended for point-of-care use and deployed in ambulances, aircraft and field settings to scan patients. If Wi-Fi and cellular signal access is limited, users may be unable to re-register the devices. 

Philips has received reports that unexpected re-registration events have prevented scanning and delayed care to patients. The reports cover the use of Lumify in environments without Wi-Fi or cellular access. 

Loss of scanning functionality or system failure may have greater consequences for Lumify than for traditional ultrasound devices, the FDA said. That conclusion reflects Lumify’s role in real-time decision-making, triage of unstable patients and access to diagnostic capabilities in mobile, underserved or remote settings.

Delays to diagnosis or treatment could lead to serious injury or death, depending on the clinical situation and patient condition, the FDA said. As of Sept. 29, Philips had reported eight serious injuries and four deaths.

To mitigate the risk, Philips recommends that healthcare professionals only use Lumify in areas with readily accessible Wi-Fi or cellular signals unless a backup ultrasound device is immediately available. The company advises users to always have backup ultrasound devices or modalities available for care. The precautions could prevent harm while Philips assesses and fixes the cause of the connection issue.

The connection between the transducer’s USB cable and a tablet or phone may disconnect or be unstable, a Philips spokesperson wrote in an email to MedTech Dive.

Philips is developing a software update, and is also working to identify the appropriate solution to the USB connection issue, the spokesperson wrote. Philips has put together a dedicated taskforce to address the situation, including offering advice and support to customers affected by the device correction.

来源:MedTech Dive 器械媒体 · medtechdive.com